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Lenient Versus Strict Rate
Control in Atrial Fibrillation
Some Devils in the Details*
D. George Wyse, MD, PHD
Calgary, Alberta, Canada
At the turn of the century, a spate of randomized, controlled
trials (RCTs) compared the 2 main pharmacological options
for rhythm management for atrial fibrillation (AF): repeated
attempts to restore and maintain sinus rhythm (rhythm
control) and controlling the heart rate without any specific
attempts to restore and maintain sinus rhythm (rate control)
(1). Largely driven by results of the 2 largest studies (2,3),
these RCTs showed little or no advantage with rhythm
control. If anything, there was a trend for an advantage with
rate control with respect to death, stroke, and cost (1,4).
imilar “no difference” results were noted later for AF
atients with congestive heart failure and reduced systolic
unction (5). A plethora of studies of various aspects of rate
ontrol should have followed such results. With the excep-
ion of RACE II (RAte Control Efficacy in permanent
trial fibrillation II), that has not happened.
See page 942
The paucity of new research on rate control for AF
reflects one of the current problems with cardiovascular
research. Whether we like it or not, the importance of
publicly funded cardiovascular research has declined dra-
matically over the past 40 years. The current cardiovascular
research agenda is driven largely by corporate-sponsored
research. As there are few or no new products for rate
control in AF, research on rate control for AF is an
orphan. This research void exists despite the current AF
epidemic (6).
Heart rate control for self-terminating and brief episodes
f AF is empirical. There is no evidence that brief episodes
f AF lead to anything more than transient deterioration of
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sanofi-aventis, Biotronik, Merck, and Bayer.ventricular function, unless there has been a preceding
episode of tachycardia-induced cardiomyopathy (7). It is
likely that a wide and lenient range of rates is acceptable in
paroxysmal AF, provided that symptoms of AF are tolerable.
The concept of heart rate targets only applies to more
continuous persistent/permanent AF. There is truly a scant
evidence base for the goals of ideal or even acceptable heart
rate control for AF. Unanswered questions about heart rate
control for AF are numerous. What was known before
RACE II is based largely on relating R-R intervals or heart
rate to hemodynamic measurements, usually derived from
echocardiograms, in a trifling number of studies in a
perilously small number of patients (8). The AFFIRM
(Atrial Fibrillation Follow-up Investigation of Rhythm
Management) investigators and the RACE II investigators
compared outcomes with heart rates resulting from their
own rather arbitrary rate control criteria (RACE II 
esting heart rate 100 beats/min; AFFIRM  resting
heart rate 80 beats/min plus criteria for activity heart rate;
average resting heart rate  83 vs. 76 beats/min, RACE II
vs. AFFIRM) and showed no difference between the 2 for
the composite outcome of death, cardiovascular hospitaliza-
tion, or myocardial infarction (9). Such a post hoc analysis
has a number of weaknesses.
To my knowledge, RACE II (10,11) is the first and only
moderate-sized RCT that prospectively compared different
criteria for heart rate control using clinical events as out-
come measures. In this respect, it is a unique and important
study. It provides the first objective information concerning
clinical criteria for satisfactory rate control for AF. That is
not to concede that it is the definitive word on this subject.
Indeed there are some “devils in the details.”
The first “devil” is found in the heart rates achieved in the
2 arms of the study. In the main report, heart rates achieved
are listed as those at the end of “titration” (median time after
randomization: lenient  0 weeks, strict  4 weeks) (11).
However, in the electronic supplement, the average heart
rates over the 3-year duration of the study were approxi-
mately 85 (lenient) beats/min and 75 (strict) beats/min.
Thus, the difference in heart rates between the 2 groups is
rather modest and similar to that seen comparing AFFIRM
and RACE II, despite the implication from the criteria
themselves or from the rates at the end of “titration.”
Importantly, the mean heart rates achieved in both groups
are considerably 100 beats/min.
The second “devil” is the composite primary outcome
chosen to overcome the modest size of the study. There are
at least 8 components in the composite (10,11). Individual
components are almost certainly not all of equal or near-
equal value or importance. In some cases, it is difficult to
imagine how heart rate would have an important impact
(e.g., the risk of bleeding).
For these reasons, the results of RACE II require some
interpretation before they are applied. The recently updated
AF treatment guidelines (12) have not been circumspect
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guidelines is a resting heart rate 110 beats/min (12), there
is an implication that a resting heart rate 100 beats/min is
acceptable. Examining the mean resting heart rate and its
variance from 1 year onward in RACE II (11), it is
extremely unlikely that any more than a handful of patients
in the lenient heart rate group had heart rates 100
eats/min. Furthermore, in the previously cited and larger
FFIRM/RACE substudy, heart rates 100 beats/min in
ermanent AF patients significantly increased risk com-
ared with successfully achieving either the AFFIRM or the
ACE rate control criteria (9). Accordingly, it seems
mprudent to imply that resting heart rates 100 beats/min
re acceptable.
In this issue of the Journal, the RACE II investigators
resent the results of a pre-specified substudy concerning
he impact of lenient or strict rate control on structural
ardiac remodeling (13). Structural cardiac remodeling dur-
ng AF is an important pathophysiological process, insofar
s atrial enlargement, ventricular enlargement, reduced sys-
olic function, and ventricular diastolic dysfunction can all
ontribute to important clinical outcomes such as stroke and
ongestive heart failure. In this substudy, differences in left
trial and left ventricular end-diastolic dimensions measured
chocardiographically at baseline and at the end of the study
ere related to baseline clinical variables and treatment
ssignment (lenient vs. strict rate control). Although as-
igned treatment had no significant impact on changes in
ardiac chamber size, female sex did. These findings are of
nterest, but, once again, there are “devils” in the details.
There was actually a “trend” for small (approximately 1-
o 2-mm and 3-ml differences between groups) favorable
hanges in left atrial and ventricular size in the strict group
ver the duration of the study. The study is too small to
xclude the possibility of a statistically significant differential
ffect of this magnitude. It seems unlikely, but not impos-
ible, that a difference of this magnitude is important
linically for some of the events in the primary outcome
easure. Once again, it is difficult to relate changes in these
chocardiographic measures to all the components of the
rimary outcome in RACE II.
The main “devil” in the substudy is that there is little or
o background information about the time course of struc-
ural remodeling from the onset of AF in humans. The time
ourse of structural cardiac remodeling from the onset of AF
as been studied in animal models (14). Something is also
nown about the time course of reverse remodeling after
nitiation of rhythm management in humans (15). There
ay be little structural change in the first couple of months
fter the onset of AF (16). Some structural remodeling may
ctually begin before the onset of AF and be a “cause” rather
han an “effect.” We know from clinical observation that
achycardia-induced cardiomyopathy takes some time to
evelop (7). Like most things in biology, the time course of
tructural remodeling during AF is probably curvilinear.
he patients in RACE II were enrolled with permanentF, and their median duration of any AF and permanent
F was around 18 and 3 months, respectively. Where is the
teep part of the curve for structural remodeling in relation
o the onset of AF, and when exactly does it begin? The
ime of intervention in RACE II may have affected the
pportunity to demonstrate a difference between the 2
reatments. Furthermore, there is no information on the
dequacy of rhythm management before enrollment in
ACE II. “Good” or “bad” rhythm management before
nrollment could affect the ability to observe a difference
etween treatments in the substudy.
One can also quibble with the methodology used in
ACE II. Would atrial volume have been a better outcome
easurement if available for all patients? Would there have
een differences if there were a measurement of diastolic
unction? Finally, it is important to note that the number of
aseline variables is rather modest. Particularly with respect
o the finding concerning female sex, it remains possible
hat other factors make important contributions to struc-
ural cardiac remodeling during AF that are not accounted
or in the model and could potentially negate the finding
ith respect to sex. Thus, although the findings of this
ubstudy are novel and important, they raise as many
uestions as they answer. More research on these important
ssues is needed. Perhaps RACE II will provide a stimulus
or further research in this area.
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